| Identification | Back Directory | [Name]
N-[(1S)-1-[4-[[4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl]sulfonyl]phenyl]ethyl]methanesulfonamide | [CAS]
447459-51-0 | [Synonyms]
SCH 336
N-[(1S)-1-[4-[[4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl]sulfonyl]phenyl]ethyl]methanesulfonamide | [Molecular Formula]
C23H25NO8S3 | [MDL Number]
MFCD09832651 | [MOL File]
447459-51-0.mol | [Molecular Weight]
539.64 |
| Chemical Properties | Back Directory | [Boiling point ]
756.6±70.0 °C(Predicted) | [density ]
1.369±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.61±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice[1]. | [in vivo]
SCH 336 (0.02, 0.2, 2.0 mg/kg; i.p.) significantly inhibits the migration of leukocytes[1]. | Animal Model: | Female B6D2/F1 mice (HU210)[1] | | Dosage: | 0.02, 0.2, 2.0 mg/kg | | Administration: | I.p. | | Result: | Significantly inhibited the migration of leukocytes into the CCL2-soaked gel foam sponge. |
| [IC 50]
hCB2-R | [storage]
Store at RT | [References]
[1] Lunn CA, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. DOI:10.1124/jpet.105.093500 |
|
|